Article info
PDFEpidemiology
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
- Correspondence to Dr Sofia Ramiro, Rheumatology, Zuyderland Medical Center, Heerlen, Limburg 6419, The Netherlands; sofiaramiro{at}gmail.com
Citation
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
Publication history
- Received July 1, 2020
- Revised July 11, 2020
- Accepted July 13, 2020
- First published July 20, 2020.
Online issue publication
August 14, 2020
Article Versions
- Previous version (20 July 2020).
- Previous version (5 August 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage